Lower Gastrointestinal Cancers

Access ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.

Thierry Andre discusses the results from the IDEA collaboration, a prospective pooled analysis of six phase III trials aimed at demonstrating the optimal duration (3 vs 6 months) of adjuvant oxaliplatin-based therapy in patients with stage III colon cancer.

Factsheets on Biomarkers

08 Sep 2016 BRAF in Colorectal Cancer Teresa Troiani
04 Aug 2015 RAS in Colorectal Cancer Teresa Troiani